Wapnick S, Grosberg S, Kinney M, LeVeen H H
JAMA. 1977 Jan 10;237(2):131-3.
30 consecutive patients with cirrhosis of the liver complicated by refractory ascites, hepatorenal syndrome, or both, received a LeVeen peritoneal-venous shunt. After surgery, these patients demonstrated a decreased abdominal girth (108 vs 93 cm, P less than .001), decreased body weight (80 vs 70 kg, P less than .001), and increased urinary flow (607 vs 4,254 ml, P less than .001). All patients had previously failed to show substantial benefit with 7 to 124 days of medical care. The mean BUN value was significantly decreased, from 39 to 23 mg/100 ml (P less than .005). Adosterone retention was reduced from a mean value of 32 to 12.8 ng/100 ml. The LeVeen continuous peritoneal-venous shunt is an important innovation that completely relieves refractory ascites in cirrhotic patients and reverses the pathophysiology of the hepatorenal syndrome.
30例连续的肝硬化合并顽固性腹水、肝肾综合征或两者皆有的患者接受了LeVeen腹腔-静脉分流术。术后,这些患者的腹围减小(108 vs 93 cm,P<0.001),体重减轻(80 vs 70 kg,P<0.001),尿流量增加(607 vs 4254 ml,P<0.001)。所有患者此前在接受7至124天的药物治疗后均未显示出显著疗效。平均血尿素氮值显著降低,从39降至23 mg/100 ml(P<0.005)。醛固酮潴留从平均值32降至12.8 ng/100 ml。LeVeen持续腹腔-静脉分流术是一项重要的创新,它能完全缓解肝硬化患者的顽固性腹水,并逆转肝肾综合征的病理生理过程。